Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes

L. Rivoltini, D. J. Loftus, K. Barracchini, F. Arienti, A. Mazzocchi, P. Squarcina, W. E. Biddison, E. Appella, G. Parmiani, F. M. Marincola

Research output: Contribution to journalArticle

Abstract

HLA-A0201-restricted melanoma-reactive CTL responses have been extensively studied; this allele is widely expressed among Caucasians, a group at risk for melanoma. We observed an unexpectedly high frequency ( 20%) of non-HLA-A0201 allelic variants (including 0205, "0204 and 0202) in a group of Italian melanoma patients. In the present study we analyzed peptide presentation by different HLA-A2 subtypes using melanoma-derived epitopes MART-l(27-35) , G9-154 and G9-280, and Flu-Ml(58-66). These peptides bound to most of the subtypes tested with IC50 values less than 500 nM, though instances of very poor binding were also noted. HLA-A0201restricted CTL displayed a limited ability to recognize peptide-pulsed EBV-B cell lines expressing different subtype molecules. Patterns of recognition varied with the peptides and effectors tested. In immunogenicity experiments, only anti-G9-280 CTL could be generated from PBL of 3β HLA-A0205 melanoma patients by in vitro peptide sensitization, while only anti-FluMl(58-66) CTL were induced in 2/2 HLA-A0202 subjects. Anti-G9-280 specific CTL recognized HLA-A0205 melanoma cells, indicating that this epitope is endogenously presented. These data imply .the necessity of subtyping patients undergoing peptide-based protocols and underline the need for additional studies of melanoma-directed T cell responses among patients expressing non-HLAA0201 subtypes.

Original languageEnglish
JournalFASEB Journal
Volume10
Issue number6
Publication statusPublished - 1996

Fingerprint

Melanoma-Specific Antigens
HLA-A2 Antigen
melanoma
Melanoma
immune response
peptides
antigens
Peptides
Epitopes
epitopes
T-cells
Human Herpesvirus 4
influenza
Inhibitory Concentration 50
B-lymphocytes
inhibitory concentration 50
Cells
B-Lymphocytes
T-lymphocytes
Alleles

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes. / Rivoltini, L.; Loftus, D. J.; Barracchini, K.; Arienti, F.; Mazzocchi, A.; Squarcina, P.; Biddison, W. E.; Appella, E.; Parmiani, G.; Marincola, F. M.

In: FASEB Journal, Vol. 10, No. 6, 1996.

Research output: Contribution to journalArticle

Rivoltini, L, Loftus, DJ, Barracchini, K, Arienti, F, Mazzocchi, A, Squarcina, P, Biddison, WE, Appella, E, Parmiani, G & Marincola, FM 1996, 'Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes', FASEB Journal, vol. 10, no. 6.
Rivoltini, L. ; Loftus, D. J. ; Barracchini, K. ; Arienti, F. ; Mazzocchi, A. ; Squarcina, P. ; Biddison, W. E. ; Appella, E. ; Parmiani, G. ; Marincola, F. M. / Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes. In: FASEB Journal. 1996 ; Vol. 10, No. 6.
@article{1e25947df0554cf9a23268dc6480d16d,
title = "Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes",
abstract = "HLA-A0201-restricted melanoma-reactive CTL responses have been extensively studied; this allele is widely expressed among Caucasians, a group at risk for melanoma. We observed an unexpectedly high frequency ( 20{\%}) of non-HLA-A0201 allelic variants (including 0205, {"}0204 and 0202) in a group of Italian melanoma patients. In the present study we analyzed peptide presentation by different HLA-A2 subtypes using melanoma-derived epitopes MART-l(27-35) , G9-154 and G9-280, and Flu-Ml(58-66). These peptides bound to most of the subtypes tested with IC50 values less than 500 nM, though instances of very poor binding were also noted. HLA-A0201restricted CTL displayed a limited ability to recognize peptide-pulsed EBV-B cell lines expressing different subtype molecules. Patterns of recognition varied with the peptides and effectors tested. In immunogenicity experiments, only anti-G9-280 CTL could be generated from PBL of 3β HLA-A0205 melanoma patients by in vitro peptide sensitization, while only anti-FluMl(58-66) CTL were induced in 2/2 HLA-A0202 subjects. Anti-G9-280 specific CTL recognized HLA-A0205 melanoma cells, indicating that this epitope is endogenously presented. These data imply .the necessity of subtyping patients undergoing peptide-based protocols and underline the need for additional studies of melanoma-directed T cell responses among patients expressing non-HLAA0201 subtypes.",
author = "L. Rivoltini and Loftus, {D. J.} and K. Barracchini and F. Arienti and A. Mazzocchi and P. Squarcina and Biddison, {W. E.} and E. Appella and G. Parmiani and Marincola, {F. M.}",
year = "1996",
language = "English",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes

AU - Rivoltini, L.

AU - Loftus, D. J.

AU - Barracchini, K.

AU - Arienti, F.

AU - Mazzocchi, A.

AU - Squarcina, P.

AU - Biddison, W. E.

AU - Appella, E.

AU - Parmiani, G.

AU - Marincola, F. M.

PY - 1996

Y1 - 1996

N2 - HLA-A0201-restricted melanoma-reactive CTL responses have been extensively studied; this allele is widely expressed among Caucasians, a group at risk for melanoma. We observed an unexpectedly high frequency ( 20%) of non-HLA-A0201 allelic variants (including 0205, "0204 and 0202) in a group of Italian melanoma patients. In the present study we analyzed peptide presentation by different HLA-A2 subtypes using melanoma-derived epitopes MART-l(27-35) , G9-154 and G9-280, and Flu-Ml(58-66). These peptides bound to most of the subtypes tested with IC50 values less than 500 nM, though instances of very poor binding were also noted. HLA-A0201restricted CTL displayed a limited ability to recognize peptide-pulsed EBV-B cell lines expressing different subtype molecules. Patterns of recognition varied with the peptides and effectors tested. In immunogenicity experiments, only anti-G9-280 CTL could be generated from PBL of 3β HLA-A0205 melanoma patients by in vitro peptide sensitization, while only anti-FluMl(58-66) CTL were induced in 2/2 HLA-A0202 subjects. Anti-G9-280 specific CTL recognized HLA-A0205 melanoma cells, indicating that this epitope is endogenously presented. These data imply .the necessity of subtyping patients undergoing peptide-based protocols and underline the need for additional studies of melanoma-directed T cell responses among patients expressing non-HLAA0201 subtypes.

AB - HLA-A0201-restricted melanoma-reactive CTL responses have been extensively studied; this allele is widely expressed among Caucasians, a group at risk for melanoma. We observed an unexpectedly high frequency ( 20%) of non-HLA-A0201 allelic variants (including 0205, "0204 and 0202) in a group of Italian melanoma patients. In the present study we analyzed peptide presentation by different HLA-A2 subtypes using melanoma-derived epitopes MART-l(27-35) , G9-154 and G9-280, and Flu-Ml(58-66). These peptides bound to most of the subtypes tested with IC50 values less than 500 nM, though instances of very poor binding were also noted. HLA-A0201restricted CTL displayed a limited ability to recognize peptide-pulsed EBV-B cell lines expressing different subtype molecules. Patterns of recognition varied with the peptides and effectors tested. In immunogenicity experiments, only anti-G9-280 CTL could be generated from PBL of 3β HLA-A0205 melanoma patients by in vitro peptide sensitization, while only anti-FluMl(58-66) CTL were induced in 2/2 HLA-A0202 subjects. Anti-G9-280 specific CTL recognized HLA-A0205 melanoma cells, indicating that this epitope is endogenously presented. These data imply .the necessity of subtyping patients undergoing peptide-based protocols and underline the need for additional studies of melanoma-directed T cell responses among patients expressing non-HLAA0201 subtypes.

UR - http://www.scopus.com/inward/record.url?scp=33749126536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749126536&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -